Flexion Therapeutics (NASDAQ:FLXN) Sets New 1-Year High at $18.38

Flexion Therapeutics Inc (NASDAQ:FLXN)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $18.38 and last traded at $18.16, with a volume of 203449 shares changing hands. The stock had previously closed at $18.25.

A number of research firms have weighed in on FLXN. ValuEngine lowered Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. BTIG Research began coverage on Flexion Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $27.00 price target on the stock. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 23rd. Finally, Northland Securities set a $20.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $24.00.

The company has a quick ratio of 5.57, a current ratio of 5.96 and a debt-to-equity ratio of 27.76. The company’s fifty day moving average price is $16.28 and its 200-day moving average price is $13.06. The stock has a market capitalization of $693.93 million, a PE ratio of -4.04 and a beta of 1.41.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.01. Flexion Therapeutics had a negative return on equity of 271.22% and a negative net margin of 266.51%. The company had revenue of $21.79 million for the quarter, compared to the consensus estimate of $18.85 million. Equities research analysts anticipate that Flexion Therapeutics Inc will post -4.07 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in FLXN. Millennium Management LLC purchased a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $148,000. Public Employees Retirement System of Ohio raised its holdings in Flexion Therapeutics by 150.1% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 61,225 shares of the specialty pharmaceutical company’s stock worth $839,000 after acquiring an additional 36,744 shares during the last quarter. California State Teachers Retirement System lifted its position in Flexion Therapeutics by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 52,632 shares of the specialty pharmaceutical company’s stock valued at $721,000 after acquiring an additional 628 shares in the last quarter. Virtu Financial LLC bought a new position in Flexion Therapeutics in the 3rd quarter valued at approximately $150,000. Finally, SG Americas Securities LLC boosted its stake in Flexion Therapeutics by 1,176.8% during the 3rd quarter. SG Americas Securities LLC now owns 151,886 shares of the specialty pharmaceutical company’s stock valued at $2,082,000 after purchasing an additional 139,990 shares during the last quarter. 89.34% of the stock is currently owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile (NASDAQ:FLXN)

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Article: Yield Curve

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.